Evidence map›Paper›PMID 29991651›Full record

ArticleScience signaling2018

IKK promotes cytokine-induced and cancer-associated AMPK activity and attenuates phenformin-induced cell death in LKB1-deficient cells.

Ricardo J Antonia, Albert S Baldwin

Abstract read
In one paragraph

Article in Science signaling, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Mechanisms and implications of podocyte autophagy in chronic kidney disease.American journal of physiology. Renal physiology · 2024
    Review
  5. Review
  6. Article
  7. AMPK and the Challenge of Treating Hypoxic Pulmonary Hypertension.International journal of molecular sciences · 2022
    Review
  8. Article
  9. IKKActa pharmaceutica Sinica. B · 2022
    Article
  10. Article
  11. Review
  12. Review
  13. Podocyte Autophagy in Homeostasis and Disease.Journal of clinical medicine · 2021
    Review
  14. Article
  15. Activation of AMPK under Hypoxia: Many Roads Leading to Rome.International journal of molecular sciences · 2020
    Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ricardo J AntoniaLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-2864-8098
Albert S BaldwinLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. albert_baldwin@med.unc.edu.ORCID 0000-0003-1246-1333
University of North Carolina at Chapel Hill · US

Funding

IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating CellsR35CA197684 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BALDWIN, ALBERT SIDNEY · 2016 to 2022
$5.8M
CANCER CELL BIOLOGY TRAINING PROGRAMT32CA071341 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHANNING J. DER, Yuliya Pylayeva-Gupta · 1996 to 2026
$5.0M
NCI NIH HHS R35 CA197684NCI NIH HHS T32 CA071341
6 · The paper itself

Abstract

The 5' AMP-activated protein kinase (AMPK) is an energy sensor that is activated upon phosphorylation of Thr

Indexed as

A549 CellsAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesAnimalsApoptosisCells, CulturedCytokinesHeLa CellsHumansI-kappa B KinaseMice, KnockoutNeoplasmsPhenforminPhosphorylationProtein Serine-Threonine KinasesSignal TransductionAMP-Activated Protein Kinase KinasesAMP-Activated Protein KinasesCHUK protein, humanCytokinesI-kappa B KinasePhenforminProtein Serine-Threonine KinasesSTK11 protein, humanThreonine

Identifiers

PMID29991651
PMCPMC6939384
OpenAlexW2857468966

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.